Trial design

DOI: 10.4244/EIJ-D-23-00206

Periprocedural continuation versus interruption of oral anticoagulant drugs during transcatheter aortic valve implantation: rationale and design of the POPular PAUSE TAVI trial

Dirk Jan van Ginkel1, MD; Willem L. Bor1, MD; Christophe L.F. Dubois2, MD, PhD; Hugo M. Aarts3,4, MD; Maxim J.P. Rooijakkers5, MD; Kees H. van Bergeijk6, MD; Liesbeth Rosseel7, MD, PhD; Leo Veenstra8, MD; Ole De Backer9, MD, PhD; Nicolas M. Van Mieghem10, MD, PhD; Frank van der Kley11, MD, PhD; Adriaan Wilgenhof3,12, MD; Remigio Leonora13, MD; Jonathan Halim14, MD; Carl E. Schotborgh15, MD, PhD; Emanuele Barbato16, MD, PhD; Jan A.S. Van Der Heyden17, MD, PhD; Peter Frambach18, MD, PhD; Bert Ferdinande19, MD, PhD; Darren Mylotte20, MD, PhD; Enrico Fabris21, MD, PhD; Benno J.W.M. Rensing1, MD, PhD; Leo Timmers1, MD, PhD; Martin J. Swaans1, MD, PhD; Jorn Brouwer1, MD, PhD; Vincent J. Nijenhuis1, MD, PhD; Joyce Peper1, MSc, PhD; Pieter A. Vriesendorp8, MD, PhD; Bas de Laat22, MSc, PhD; Marisa Ninivaggi22, MSc, PhD; Hendrik Stragier23,24, MD; Michiel Voskuil4, MD, PhD; Alexander J.J. IJsselmuiden14, MD, PhD; Renicus S. Hermanides11, MD, PhD; Pierfrancesco Agostoni11, MD, PhD; Arnoud W.J. van 't Hof8,24, MD, PhD; Joanna J. Wykrzykowska6, MD, PhD; Niels van Royen5, MD, PhD; Ronak Delewi3, MD, PhD; Jurrien M. ten Berg1,24, MD, PhD

Abstract

About one-third of patients undergoing transcatheter aortic valve implantation (TAVI) use oral anticoagulants (OAC), mainly due to atrial fibrillation. General guidelines advise interrupting OAC in patients with a high risk of bleeding undergoing interventions. However, preliminary observational data suggest that the continuation of OAC during TAVI is safe and may reduce the risk of periprocedural thromboembolic events. The Periprocedural Continuation Versus Interruption of Oral Anticoagulant Drugs During Transcatheter Aortic Valve Implantation (POPular PAUSE TAVI) is a multicentre, randomised clinical trial with open-label treatment and blinded endpoint assessment. Patients are randomised 1:1 to periprocedural continuation versus interruption of OAC and are stratified for vitamin K antagonist or direct oral anticoagulant use. The primary endpoint is a composite of cardiovascular mortality, all stroke, myocardial infarction, major vascular complications and type 2-4 bleeding within 30 days after TAVI, according to the Valve Academic Research Consortium-3 criteria. Secondary endpoints include separate individual and composite outcomes, quality of life and cost-effectiveness. Since continuation of OAC is associated with the ancillary benefit that it simplifies periprocedural management, the primary outcome is first analysed for non-inferiority; if non-inferiority is proven, superiority will be tested. Recruitment started in November 2020, and the trial will continue until a total of 858 patients have been included and followed for 90 days. In summary, POPular PAUSE TAVI is the first randomised clinical trial to assess the safety and efficacy of periprocedural continuation versus interruption of OAC in patients undergoing TAVI.

Sign in to read
the full article

Forgot your password?
No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Volume 19 Number 9
Nov 17, 2023
Volume 19 Number 9
View full issue


Key metrics

Suggested by Cory

Editorial

10.4244/EIJ-E-22-00055 Feb 6, 2023
Continuation of oral anticoagulation during transcatheter aortic valve implantation: time to change practice?
ten Berg J and van Ginkel DJ
free

10.4244/EIJV11SWA28 Sep 17, 2015
Antithrombotic therapy in TAVI patients: changing concepts
Gargiulo G et al
free

10.4244/EIJV15I7A102 Sep 20, 2019
Antithrombotic therapy after TAVI: where are we going?
Wilkins B et al
free

10.4244/EIJV9SSA9 Sep 15, 2013
Antithrombotic and antiplatelet therapy in TAVI patients: a fallow field?
Collet J and Montalescot G
free

AORTIC VALVE INTERVENTIONS

10.4244/EIJV12SYA12 Sep 18, 2016
Upcoming TAVI trials: rationale, design and impact on clinical practice
Capodanno D and Leon MB
free

EXPERT REVIEW

10.4244/EIJ-D-18-00454 Sep 7, 2018
TAVI and the brain: update on definitions, evidence of neuroprotection and adjunctive pharmacotherapy
Lansky AJ et al
free
Trending articles
153.65

Clinical research

10.4244/EIJ-D-20-01125 Oct 20, 2021
An upfront combined strategy for endovascular haemostasis in transfemoral transcatheter aortic valve implantation
Costa G et al
free
54.9

Expert review

10.4244/EIJ-D-21-01010 Jun 24, 2022
Device-related thrombus following left atrial appendage occlusion
Simard T et al
free
43.75

Clinical Research

10.4244/EIJ-D-21-01091 Aug 5, 2022
Lifetime management of patients with symptomatic severe aortic stenosis: a computed tomography simulation study
Medranda G et al
free
39.1

Clinical research

10.4244/EIJ-D-22-00558 Feb 6, 2023
Permanent pacemaker implantation and left bundle branch block with self-expanding valves – a SCOPE 2 subanalysis
Pellegrini C et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved